NCT02362594 2026-03-05MK-3475-054Merck Sharp & Dohme LLCPhase 3 Active not recruiting1,019 enrolled 16 charts 1 FDA
NCT03969004 2025-09-19Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell CarcinomaRegeneron PharmaceuticalsPhase 3 Active not recruiting415 enrolled 1 FDA
NCT03470922 2025-09-09RELATIVITY-047Bristol-Myers SquibbPhase 2/3 Active not recruiting714 enrolled 17 charts 1 FDA
NCT04099251 2025-08-27CheckMate76KBristol-Myers SquibbPhase 3 Active not recruiting790 enrolled 18 charts 1 FDA
NCT03212404 2025-02-03Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersCheckpoint Therapeutics, Inc.Phase 1 Active not recruiting272 enrolled 1 FDA
NCT03553836 2024-11-29KEYNOTE-716Merck Sharp & Dohme LLCPhase 3 Active not recruiting976 enrolled 15 charts 1 FDA